⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SMMT News
Summit Therapeutics Inc. Common Stock
Summit Therapeutics to Present at Upcoming Investor Conferences
businesswire.com
SMMT
Form 8-K
sec.gov
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
businesswire.com
SMMT
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
businesswire.com
SMMT
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
businesswire.com
SMMT
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
AVBP
SMMT
MRUS
MRK
GNPX
CGEM
ABBV
BMY
BDTX
LTRN
PFE
JNJ
LLY
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
businesswire.com
SMMT
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
businesswire.com
SMMT
GSK
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
businesswire.com
SMMT
Summit Therapeutics to Present at the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
SMMT